S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
S&P 500   3,923.68
DOW   31,490.07
QQQ   291.14
OTCMKTS:EKTAY

Elekta AB (publ) (EKTAY) Stock Forecast, Price & News

$7.26
-0.15 (-2.02%)
(As of 05/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.17
$7.26
50-Day Range
$6.31
$8.35
52-Week Range
$6.24
$15.56
Volume
20,407 shs
Average Volume
30,895 shs
Market Capitalization
$2.68 billion
P/E Ratio
21.35
Dividend Yield
2.02%
Beta
1.04
30 days | 90 days | 365 days | Advanced Chart
Receive EKTAY News and Ratings via Email

Sign-up to receive the latest news and ratings for Elekta AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Elekta AB (publ) logo

About Elekta AB (publ)

Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:EKTAY
Employees
4,342
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.57 billion
Cash Flow
$0.76 per share
Book Value
$2.44 per share

Profitability

Net Income
$143.46 million
Pretax Margin
9.98%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$2.68 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
2/24/2022
Ex-Dividend for 3/18 Dividend
2/25/2022
Dividend Payable
3/18/2022
Today
5/18/2022
Fiscal Year End
4/30/2023

MarketRank

Overall MarketRank

2.15 out of 5 stars

Analyst Opinion: 2.7Community Rank: 3.7Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -













Elekta AB (publ) (OTCMKTS:EKTAY) Frequently Asked Questions

Is Elekta AB (publ) a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elekta AB (publ) in the last year. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" Elekta AB (publ) stock.
View analyst ratings for Elekta AB (publ)
or view top-rated stocks.

Are investors shorting Elekta AB (publ)?

Elekta AB (publ) saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 8,500 shares, a decrease of 50.9% from the April 15th total of 17,300 shares. Based on an average daily volume of 77,000 shares, the short-interest ratio is presently 0.1 days.
View Elekta AB (publ)'s Short Interest
.

How were Elekta AB (publ)'s earnings last quarter?

Elekta AB (publ) (OTCMKTS:EKTAY) announced its quarterly earnings data on Thursday, February, 24th. The company reported $0.07 earnings per share for the quarter. The firm earned $399.40 million during the quarter. Elekta AB (publ) had a trailing twelve-month return on equity of 15.96% and a net margin of 7.74%.
View Elekta AB (publ)'s earnings history
.

How often does Elekta AB (publ) pay dividends? What is the dividend yield for Elekta AB (publ)?

Elekta AB (publ) declared a dividend on Friday, February 18th. Shareholders of record on Monday, February 28th will be given a dividend of $0.0805 per share on Friday, March 18th. This represents a yield of 2.67%. The ex-dividend date of this dividend is Friday, February 25th.
View Elekta AB (publ)'s dividend history
.

Is Elekta AB (publ) a good dividend stock?

Elekta AB (publ) pays an annual dividend of $0.15 per share and currently has a dividend yield of 2.02%. The dividend payout ratio of Elekta AB (publ) is 44.12%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Elekta AB (publ) will have a dividend payout ratio of 38.46% next year. This indicates that Elekta AB (publ) will be able to sustain or increase its dividend.
View Elekta AB (publ)'s dividend history.

What price target have analysts set for EKTAY?

3 brokerages have issued 12-month target prices for Elekta AB (publ)'s stock. Their forecasts range from $69.00 to $69.00. On average, they expect Elekta AB (publ)'s share price to reach $69.00 in the next twelve months. This suggests a possible upside of 850.4% from the stock's current price.
View analysts' price targets for Elekta AB (publ)
or view top-rated stocks among Wall Street analysts.

Who are Elekta AB (publ)'s key executives?
Elekta AB (publ)'s management team includes the following people:
  • Dr. Laurent Leksell, Founder & Chairman (Age 70)
  • Mr. Gustaf Salford, Pres & CEO (Age 45)
  • Mr. Tobias Hagglov, Chief Financial Officer (Age 44)
  • Cecilia Ketels, Head of Investor Relations
  • Mr. Jonas Bolander, Gen. Counsel, Sec. & Exec. VP (Age 56)
  • Mr. Mattias Thorsson, VP and Head of Corp. Communications & Public Affairs
  • Ms. Karin Svenske Nyberg, Exec. VP of HR (Age 56)
  • Mr. James P. Hoey, Head of External Relations (Age 64)
  • Mr. John Lapré, Pres of Brachy Solutions (Age 58)
  • Mr. Maurits Wolleswinkel, Chief Product Officer (Age 51)
What is Elekta AB (publ)'s stock symbol?

Elekta AB (publ) trades on the OTCMKTS under the ticker symbol "EKTAY."

How do I buy shares of Elekta AB (publ)?

Shares of EKTAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Elekta AB (publ)'s stock price today?

One share of EKTAY stock can currently be purchased for approximately $7.26.

How much money does Elekta AB (publ) make?

Elekta AB (publ) has a market capitalization of $2.68 billion and generates $1.57 billion in revenue each year. The company earns $143.46 million in net income (profit) each year or $0.339990 on an earnings per share basis.

How many employees does Elekta AB (publ) have?

Elekta AB (publ) employs 4,342 workers across the globe.

What is Elekta AB (publ)'s official website?

The official website for Elekta AB (publ) is www.elekta.com.

How can I contact Elekta AB (publ)?

Elekta AB (publ)'s mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company can be reached via phone at (685) 872-5400, via email at [email protected], or via fax at 46-8-587-255-00.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.